They can interact with challenging biological targets while offering opportunities for greater structural flexibility and design.
Peptide drug development is expected to remain an important area of innovation in 2027, particularly for targets that are difficult to address with conventional small molecules. Stapled and macrocyclic peptides are gaining attention because they can provide greater stability while maintaining strong interactions with challenging protein targets. World BI is again organizing a conference next year on Drug Discovery Innovation Programme on 17 June in Princeton, New Jersey, USA.
Why Conventional Peptides Have Limitations?
Despite their strong target-recognition potential, conventional peptides face several challenges:
- Vulnerability to enzymatic degradation.
- Structural flexibility.
- Difficult cellular delivery
- Limited metabolic stability.
- Challenges with oral administration.
These limitations have encouraged researchers to explore more engineered peptide formats.
Stapled Peptides: Locking Peptides Into Shape
Stapled peptides use a molecular “staple” to restrict flexibility and maintain a more stable structure. This can help improve how the peptide interacts with its target.
Potential benefits include:
- Greater structural stability.
- Improved resistance to enzymatic breakdown.
- Stronger and more selective target interactions.
- Greater potential for intracellular targeting.
- More flexibility in peptide design
How Stapled Peptides Overcome Traditional Peptide Limitations
Stapled peptides are designed to overcome some of the weaknesses of conventional peptides. By introducing a chemical linker that locks a peptide into its active helical structure, researchers can improve its stability and help maintain the shape required for target binding. The approach has shown potential for increasing target affinity, protecting peptides from enzymatic degradation, and improving cellular penetration.
This is particularly important for protein–protein interactions (PPIs), which often involve large, relatively flat surfaces that can be difficult for conventional small molecules to target. Stapled peptides can interact with these surfaces while potentially reaching intracellular targets that larger biologics cannot easily access. The review also highlights examples targeting pathways such as BCL-2 and p53-MDM2, demonstrating the broader potential of this approach in drug discovery.
Macrocycles: A Middle Ground in Drug Design
Macrocyclic peptides contain a closed, ring-like structure that helps maintain a defined three-dimensional shape. Their size and complexity allow them to interact with challenging targets while remaining smaller than many biologic therapies.
Their constrained structures may improve binding, selectivity, and stability, making them attractive for:
- Difficult protein-protein interactions.
- Intracellular proteins.
- Complex signaling pathways.
- Previously challenging therapeutic targets.
- Targets requiring larger binding surfaces.
Why This Matters for Drug Discovery in 2027
Stapled peptides and macrocycles represent more than new therapeutic options. They reflect a shift toward selecting the molecular format that best matches the biology of a target.
Several advances are supporting this progress:
- Computational drug design.
- AI-powered molecular discovery.
- High-throughput screening.
- Advanced peptide synthesis.
- Structural biology.
- Drug delivery technologies
AI can also help predict structures, optimize peptide sequences, and prioritize promising candidates for laboratory testing.
The Road Ahead
Peptide and macrocyclic candidates still face challenges involving delivery, stability, manufacturing, and pharmacokinetics. However, advances in medicinal chemistry, peptide engineering, and computational design are creating new opportunities.
As researchers focus on increasingly complex biological targets, stapled peptides and macrocycles could bridge the gap between conventional small molecules and larger biologic therapies.
Conclusion
Peptide drug discovery is entering an exciting phase. Stapled peptides and macrocycles offer new ways to approach targets that have traditionally been difficult to address.
In 2027, these modalities could provide a valuable middle ground, combining precise target engagement with some of the design advantages of smaller compounds. As AI, structural biology, and peptide engineering continue to advance, their role in next-generation drug discovery could grow significantly.
World BI Drug Discovery Innovation Programme
The Drug Discovery Innovation Programme organized by World BI is a leading global event that brings together pharmaceutical executives, researchers, biotech innovators, and technology experts to explore the latest advancements in drug discovery and early development.
Organized by World BI, the conference focuses on key topics such as AI-driven drug discovery, target identification, precision medicine, biomarker development, computational drug design, and emerging therapeutic modalities. The programme provides a collaborative platform for industry leaders to share insights, address challenges, and accelerate the development of innovative therapies that improve patient outcomes worldwide.